AtCor's pressure rises
Wednesday, 30 July, 2008
AtCor Medical Holdings [ASX: ACG] has recorded its best sales figures ever, totalling around $6.5 million in 2008.
This represents a 47 per cent increase over last year's sales.
The largest gain was in Europe, where sales increased by 59 per cent. In North America sales increased by 46 per cent, and rest of the world by eight per cent.
The company's main product, the SphygmoCor system, identifies the effects of reflected blood pressure in the central aortic pressure wave.
Last week, the company reported two contracts for a total of US$1.6 million for pharmaceutical company.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
